Delek US Holdings' low P/S ratio is due to predicted revenue decline. Investors see no significant potential for revenue growth to justify a higher P/S ratio. Without major changes, a significant stock price increase is unlikely. The company's weak outlook is pressuring the shares downwards.
The board of Delek US Holdings expresses positive sentiment towards the appointment of Ms. Benson, highlighting her experience in risk management, capital markets, and green energies as instrumental for the company's strategic initiatives.
Delek's lower Return on Equity (ROE) coupled with high debt levels make it less attractive for investment. Investors should also consider profit growth rates and market expectations before investing in Delek or similar companies.
Delek US股票讨论区
2022前三季度营收大幅增长1倍至157亿,营业利润增长6倍到6亿,净利润则达到了4亿。
目前市盈率TTM 6.6,考虑到利润暴增的持续性,吸引力不大。
• $La-Z-Boy(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $辉瑞(PFE.US)$)
• $Ikena Oncology(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
In trading, often what a person needs is not some brilliant mathematically-oriented mind, but just a little bit of common sense, patience, humility, and discernment.
Patience, persistence, and practice— your three best friends.
Don’t ditch them.
$Palantir(PLTR.US)$ $Delek US(DK.US)$ $Apex Technology Acquisition Corp(APXT.US)$ $美国超微公司(AMD.US)$ $波音(BA.US)$ $Bed Bath & Beyond Inc(BBBY.US)$ $Jumia Technologies(JMIA.US)$
暂无评论